191 related articles for article (PubMed ID: 28506425)
21. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
22. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.
Allen GP; Kaatz GW; Rybak MJ
Antimicrob Agents Chemother; 2003 Aug; 47(8):2606-14. PubMed ID: 12878526
[TBL] [Abstract][Full Text] [Related]
23. Cross-resistance, relatedness and allele analysis of fluoroquinolone-resistant US clinical isolates of Streptococcus pneumoniae (1998-2000).
Davies TA; Goldschmidt R; Pfleger S; Loeloff M; Bush K; Sahm DF; Evangelista A
J Antimicrob Chemother; 2003 Aug; 52(2):168-75. PubMed ID: 12837740
[TBL] [Abstract][Full Text] [Related]
24. Prevalence of single mutations in topoisomerase type II genes among levofloxacin-susceptible clinical strains of Streptococcus pneumoniae isolated in the United States in 1992 to 1996 and 1999 to 2000.
Davies TA; Evangelista A; Pfleger S; Bush K; Sahm DF; Goldschmidt R
Antimicrob Agents Chemother; 2002 Jan; 46(1):119-24. PubMed ID: 11751121
[TBL] [Abstract][Full Text] [Related]
25. Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000.
Critchley IA; Blosser-Middleton RS; Jones ME; Karlowsky JA; Karginova EA; Thornsberry C; Sahm DF
Int J Antimicrob Agents; 2002 Aug; 20(2):100-7. PubMed ID: 12297358
[TBL] [Abstract][Full Text] [Related]
26. The molecular epidemiology of Streptococcus pneumoniae with quinolone resistance mutations.
Richter SS; Heilmann KP; Beekmann SE; Miller NJ; Rice CL; Doern GV
Clin Infect Dis; 2005 Jan; 40(2):225-35. PubMed ID: 15655739
[TBL] [Abstract][Full Text] [Related]
27. Levofloxacin-resistant invasive Streptococcus pneumoniae in the United States: evidence for clonal spread and the impact of conjugate pneumococcal vaccine.
Pletz MW; McGee L; Jorgensen J; Beall B; Facklam RR; Whitney CG; Klugman KP
Antimicrob Agents Chemother; 2004 Sep; 48(9):3491-7. PubMed ID: 15328116
[TBL] [Abstract][Full Text] [Related]
28. Are fluoroquinolone-susceptible isolates of Streptococcus pneumoniae really susceptible? A comparison of resistance mechanisms in Canadian isolates from 1997 and 2003.
Schurek KN; Adam HJ; Siemens CG; Hoban CJ; Hoban DJ; Zhanel GG
J Antimicrob Chemother; 2005 Oct; 56(4):769-72. PubMed ID: 16126779
[TBL] [Abstract][Full Text] [Related]
29. Characterization of the quinolone resistant determining regions in clinical isolates of pneumococci collected in Canada.
Patel SN; Melano R; McGeer A; Green K; Low DE
Ann Clin Microbiol Antimicrob; 2010 Jan; 9():3. PubMed ID: 20082699
[TBL] [Abstract][Full Text] [Related]
30. Prevalence of first-step mutants among levofloxacin-susceptible isolates of Streptococcus pneumoniae in north Lebanon.
Dabboussi F; Allouche S; Mallat H; Hamze M
J Chemother; 2013 Dec; 25(6):328-31. PubMed ID: 24091419
[TBL] [Abstract][Full Text] [Related]
31. Incidence and epidemiology of levofloxacin resistance in Streptococcus pneumoniae: experience from a tertiary referral hospital in England.
Orr D; Wilkinson P; Moyce L; Martin S; George R; Pichon B
J Antimicrob Chemother; 2010 Mar; 65(3):449-52. PubMed ID: 20019170
[TBL] [Abstract][Full Text] [Related]
32. Pharmacodynamic characterization of efflux and topoisomerase IV-mediated fluoroquinolone resistance in Streptococcus pneumoniae.
Madaras-Kelly KJ; Daniels C; Hegbloom M; Thompson M
J Antimicrob Chemother; 2002 Aug; 50(2):211-8. PubMed ID: 12161401
[TBL] [Abstract][Full Text] [Related]
33. Emergence of the first levofloxacin-resistant strains of Streptococcus agalactiae isolated in Italy.
Piccinelli G; Gargiulo F; Corbellini S; Ravizzola G; Bonfanti C; Caruso A; De Francesco MA
Antimicrob Agents Chemother; 2015 Apr; 59(4):2466-9. PubMed ID: 25666148
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamics of moxifloxacin and levofloxacin at simulated epithelial lining fluid drug concentrations against Streptococcus pneumoniae.
Florea NR; Tessier PR; Zhang C; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Apr; 48(4):1215-21. PubMed ID: 15047522
[TBL] [Abstract][Full Text] [Related]
35. Novel Ser79Leu and Ser81Ile substitutions in the quinolone resistance-determining regions of ParC topoisomerase IV and GyrA DNA gyrase subunits from recent fluoroquinolone-resistant Streptococcus pneumoniae clinical isolates.
Korzheva N; Davies TA; Goldschmidt R
Antimicrob Agents Chemother; 2005 Jun; 49(6):2479-86. PubMed ID: 15917550
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of clinical Streptococcus pneumoniae isolates with reduced susceptibility to fluoroquinolones emerging in Italy.
Montanari MP; Tili E; Cochetti I; Mingoia M; Manzin A; Varaldo PE
Microb Drug Resist; 2004; 10(3):209-17. PubMed ID: 15383164
[TBL] [Abstract][Full Text] [Related]
37. Molecular characterization of quinolone-insensitive Streptococcus pneumoniae isolates from Japanese patients.
Araki N; Yanagihara K; Matsukawa Y; Harada Y; Migiyama Y; Nagaoka K; Yamada K; Morinaga Y; Hasegawa H; Kohno S; Kamihira S
J Infect Chemother; 2013 Apr; 19(2):356-9. PubMed ID: 22911090
[TBL] [Abstract][Full Text] [Related]
38. Fluoroquinolone resistance in Streptococcus pneumoniae: area under the concentration-time curve/MIC ratio and resistance development with gatifloxacin, gemifloxacin, levofloxacin, and moxifloxacin.
LaPlante KL; Rybak MJ; Tsuji B; Lodise TP; Kaatz GW
Antimicrob Agents Chemother; 2007 Apr; 51(4):1315-20. PubMed ID: 17296740
[TBL] [Abstract][Full Text] [Related]
39. Frequency of 1st- and 2nd-step topoisomerase mutations in Streptococcus pneumoniae following levofloxacin and moxifloxacin exposure.
Hovde LB; Simonson DA; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Mar; 60(3):295-9. PubMed ID: 18053674
[TBL] [Abstract][Full Text] [Related]
40. Fluoroquinolone resistance mutations in the parC, parE, and gyrA genes of clinical isolates of viridans group streptococci.
González I; Georgiou M; Alcaide F; Balas D; Liñares J; de la Campa AG
Antimicrob Agents Chemother; 1998 Nov; 42(11):2792-8. PubMed ID: 9797205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
